Tag: expedited safety reporting

Common Pitfalls in SUSAR Detection & Expedited Reporting—and How to Avoid Regulatory Findings

November 22, 2025November 17, 2025 digi

Common Pitfalls in SUSAR Detection & Expedited Reporting—and How to Avoid Regulatory Findings Common Pitfalls in SUSAR Detection & Expedited Reporting—and How to Avoid Regulatory Findings In the highly regulated environment of clinical research, the accurate detection and expedited reporting of Suspected Unexpected Serious Adverse Reactions (SUSARs) are critical components of ensuring patient safety, maintaining…

SUSAR Detection & Expedited Reporting

Aligning SUSAR Detection & Expedited Reporting With GCP, ICH E2A–E2F and Local Regulations

November 22, 2025November 17, 2025 digi

Aligning SUSAR Detection & Expedited Reporting With GCP, ICH E2A–E2F and Local Regulations Aligning SUSAR Detection & Expedited Reporting With GCP, ICH E2A–E2F and Local Regulations In the complex landscape of clinical trials, the detection and reporting of Suspected Unexpected Serious Adverse Reactions (SUSARs) are critical components that must align with regulatory frameworks such as…

SUSAR Detection & Expedited Reporting

Digital Tools and Automation to Streamline SUSAR Detection & Expedited Reporting

November 22, 2025November 17, 2025 digi

Digital Tools and Automation to Streamline SUSAR Detection & Expedited Reporting Digital Tools and Automation to Streamline SUSAR Detection & Expedited Reporting In the landscape of clinical research, the identification and reporting of Serious Unexpected Suspected Adverse Reactions (SUSARs) is critical to ensuring participant safety and maintaining compliance with regulatory guidelines. This article provides a…

SUSAR Detection & Expedited Reporting

SUSAR Detection & Expedited Reporting: End-to-End Compliance Framework for Global Clinical Trials

November 22, 2025November 17, 2025 digi

SUSAR Detection & Expedited Reporting: End-to-End Compliance Framework for Global Clinical Trials SUSAR Detection & Expedited Reporting: End-to-End Compliance Framework for Global Clinical Trials Introduction to SUSAR in Clinical Trials Serious Unexpected Suspected Adverse Reactions (SUSARs) play a critical role in ensuring patient safety during clinical trials. The detection and expedited reporting of SUSARs are…

SUSAR Detection & Expedited Reporting

SUSAR Detection & Expedited Reporting in Practice: Step-by-Step Guide for Sponsors and CROs

November 22, 2025November 17, 2025 digi

SUSAR Detection & Expedited Reporting in Practice: Step-by-Step Guide for Sponsors and CROs SUSAR Detection & Expedited Reporting in Practice: Step-by-Step Guide for Sponsors and CROs Introduction to SUSARs in Clinical Trials Safety monitoring in clinical trials is paramount, especially when it involves vulnerable patient populations, such as those undergoing treatment for non-small cell lung…

SUSAR Detection & Expedited Reporting

SUSAR Reporting & Expedited Timelines: Definitions, Global Workflows, and Inspection-Ready Controls

November 7, 2025 digi

SUSAR Reporting & Expedited Timelines: Definitions, Global Workflows, and Inspection-Ready Controls Serious, Unexpected, and Suspected: Mastering SUSAR Reporting and the Global Expedited Clock What Triggers a SUSAR—and Who Must Receive It SUSARs—Suspected Unexpected Serious Adverse Reactions—sit at the heart of expedited pharmacovigilance. A SUSAR is a serious adverse reaction (i.e., an AE judged to have…

Pharmacovigilance & Drug Safety, SUSAR Reporting & Expedited Timelines

Communication with IRB/Regulators: A Regulator-Ready System for Fast, Clear, and Defensible Safety Notices (2025)

November 3, 2025 digi

Communication with IRB/Regulators: A Regulator-Ready System for Fast, Clear, and Defensible Safety Notices (2025) Building Inspection-Ready Communications with IRBs and Regulators During Safety Events Purpose, Principles, and the Global Ethics–Regulatory Frame Clear, timely communication with Institutional Review Boards/Independent Ethics Committees (IRBs/IECs) and health authorities is the fulcrum of credible safety management. The aim is not…

Adverse Event Reporting & SAE Management, Communication with IRB/Regulators

SUSAR Detection & Expedited Reporting: A Regulator-Ready Blueprint for Speed, Accuracy, and Traceability (2025)

November 2, 2025 digi

SUSAR Detection & Expedited Reporting: A Regulator-Ready Blueprint for Speed, Accuracy, and Traceability (2025) Engineering SUSAR Detection and Expedited Reporting That Withstand Inspection Purpose, Principles, and the Global Frame for SUSARs Suspected Unexpected Serious Adverse Reactions (SUSARs) sit at the intersection of clinical care, regulatory duty, and ethics. A single missed or late report can…

Adverse Event Reporting & SAE Management, SUSAR Detection & Expedited Reporting

Mastering FDA Clinical Rules: 21 CFR Parts 50, 54, 56, 312, and 314 for Inspection-Ready Trials

October 24, 2025 digi

Mastering FDA Clinical Rules: 21 CFR Parts 50, 54, 56, 312, and 314 for Inspection-Ready Trials FDA Clinical Requirements Unpacked: Consent, IRBs, INDs, and NDAs—A Practical Compliance Guide What the Rules Cover—and How They Fit Together For sponsors, CROs, and research sites operating in the United States, five FDA regulatory parts shape day-to-day conduct and…

FDA (21 CFR Parts 50, 54, 56, 312, 314), Regulatory Frameworks & Global Guidelines